Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Galcanezumab reduces cluster headache attack frequency

Key clinical point: Galcanezumab reduces weekly cluster headache attack frequency.

Major finding: Mean weekly attack frequency decreased by 8.7 days in the galcanezumab group.

Study details: An eight-week, double-blind, placebo-controlled trial of 106 patients with episodic cluster headache.

Disclosures: Eli Lilly and Co. sponsored the study, and Dr. Dodick has a consulting relationship with the company.

Citation:

Bardos JN et al. AAN 2019. Abstract 02.004.